D. Spigel, K. Goto, D. Camidge, Y. Elamin, A. D. de Langen, N. Leighl, A. Minchom, Z. Piotrowska, D. Planchard, K. Reckamp, F. Albayya, Jennifer Green, Sean H. J. Kim, M. Louie-Gao, R. Sawtell, A. Zalutskaya, Byoung Chul Co
{"title":"P230:一项针对表皮生长因子受体(EGFR)耐药突变的高效选择性抑制剂BLU-945在EGFR突变的非小细胞肺癌(NSCLC)患者中的1/2期研究","authors":"D. Spigel, K. Goto, D. Camidge, Y. Elamin, A. D. de Langen, N. Leighl, A. Minchom, Z. Piotrowska, D. Planchard, K. Reckamp, F. Albayya, Jennifer Green, Sean H. J. Kim, M. Louie-Gao, R. Sawtell, A. Zalutskaya, Byoung Chul Co","doi":"10.1158/1535-7163.targ-21-p230","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)\",\"authors\":\"D. Spigel, K. Goto, D. Camidge, Y. Elamin, A. D. de Langen, N. Leighl, A. Minchom, Z. Piotrowska, D. Planchard, K. Reckamp, F. Albayya, Jennifer Green, Sean H. J. Kim, M. Louie-Gao, R. Sawtell, A. Zalutskaya, Byoung Chul Co\",\"doi\":\"10.1158/1535-7163.targ-21-p230\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20348,\"journal\":{\"name\":\"Poster Presentations - Proffered Abstracts\",\"volume\":\"30 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Presentations - Proffered Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.targ-21-p230\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)